Zynerba Discontinues Development Of Cannabidiol Gel In Epileptic Disorders

Zynerba Pharmaceuticals Inc ZYNE has decided not to advance Zygel against developmental and epileptic encephalopathies (DEE).

  • The decision was in line with the feedback from the FDA, which indicated that the selection of a specific DEE syndrome would be required to support its clinical trials for a pediatric indication, the company said. 
  • Instead, Zynerba now plans to move the investigational cannabidiol gel against Fragile X syndrome (FXS), autism spectrum disorder (ASD), and 22q11.2 deletion syndrome (22q).
  • Related: Zynerba Stock Moves Higher On Long-Term Zygel Data In Autistic Children.
  • The data for Zygel from a pivotal Phase 3 trial in FXS is expected in H2 of 2023.
  • Meanwhile, CEO Armando Anido expects its INSPIRE trial for Zygel in 22q to generate topline data in mid-2022.
  • “Putting resources behind a second indication beyond FXS and completing the INSPIRE trial is consistent with our mission of being a leader in rare and near-rare neuropsychiatric disorders, including FXS, ASD, and 22q,” he added.
  • With cash and equivalents at $75.6 million as of September 30, 2021, Zynerba believes its funding would be sufficient until H2 2023. 
  • Price Action: ZYNE shares closed at $2.95 on Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsPenny StocksBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!